Exploring the Sn binding pockets in gingipains by newly developed inhibitors: Structure-based design, chemistry, and activity

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1744-1753

  Bialas, Arkadiusz ^a   Grembecka, Jolanta ^a   Krowarsch, Daniel ^b   Otlewski, Jacek ^b   Potempa, Jan ^c,d   Mucha, Artur ^a  

^a WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d University of Georgia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINE PROTEINASE; GINGIPAIN INHIBITOR; GINGIPAIN K; GINGIPAIN R; KETONE; LYSINE; PROTEINASE INHIBITOR; TIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; PERIODONTAL DISEASE; PORPHYROMONAS GINGIVALIS; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

ADHESINS, BACTERIAL; AMINO ACID CHLOROMETHYL KETONES; AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 33644857269     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0600141     Document Type: Article

References (49)

1. DeStefano, F.; Anda, R. F.; Kahn, H. S.; Williamson, D. F.; Russell, C. M. Dental disease and risk of coronary heart disease and mortality. Br. Med. J. 1993, 306, 688-691.
2. Beck, J. D.; Pankow, J.; Tyroler, H. A.; Offenbacher, S. Dental infections and atherosclerosis. Am. Heart J. 1999, 138, S528-533.
3. Scannapieco, F. A. Role of oral bacteria in respiratory infection. J. Periodontol. 1999, 70, 793-802.
4. ( 4) Teng, Y. T.; Taylor, G. W.; Scannapieco, F.; Kinane, D. F.; Curtis, M.; et al. Periodontal health and systemic disorders. J. Can. Dent. Assoc. 2002, 68, 188-192.
5. Shapira, L.; Ayalon, S.; Brenner, T. Effects of Porphyromonas gingivalis on the central nervous system; Activation of glial cells and exacerbation of experimental autoimmune encephalomyelitis. J. Periodontol. 2002, 73, 511-516.
6. Romero, B. C.; Chiquito, C. S.; Elejalde, L. E.; Bernardoni, C. B. Relationship between periodontal disease in pregnant women and the nutritional condition of their newborns. J. Periodontol. 2002, 73. 1177-1183.
7. Jeffcoat, M. K.; Hauth, J. C.; Geurs, N. C.; Reddy, M. S.; Cliver, S. P.; et al. Periodontal disease and preterm birth; Results of a pilot intervention study. J. Periodontol. 2003, 74, 1214-1218.
8. Kadowaki, T.; Baba, A.; Abe, N.; Takii, R.; Hashimoto, M.; et al. Suppression of pathogenicity of Porphyromonas gingivalis by newly developed gingipain inhibitors. Mol. Pharmacol. 2004, 66, 1599-1606.
9. Slots, J.; Bragd, L.; Wikstrom, M.; Dahlen, G. The occurrence of Actinobacillus actinomvcetemcomitans, Bacteroides gingivalis and Bacteroides intermedius in destructive periodontal disease in adults. J. Clin. Periodontol. 1986, 13, 570-577.
10. Holt, S. C.; Ebersole, J.; Felton, J.; Brunsvold, M.; Kornman, K. S. Implantation of Bacteroides gingivalis in nonhuman primates initiates progression of periodontitis. Science 1988, 239, 55-57.
11. Pike, R.; McGraw, W.; Potempa, J.; Travis, J. Lysine- and arginine-specific proteinases from Porphyromonas gingivalis. Isolation, characterization, and evidence for the existence of complexes with hemagglutinins. J. Biol. Chem. 1994, 269, 406-411.
12. Pike, R.; McGraw, W.; Potempa, J.; Travis, J. Lysine- and arginine-specific proteinases from Porphyromonas gingivalis. Isolation, characterization, and evidence for the existence of complexes with hemagglutinins. J. Biol. Chem. 1994, 269, 406-411.
13. Potempa, J.; Mikolajczyk-Pawlinska, J.; Brassell, D.; Nelson, D.; Thogersen, I. B.; et al. Comparative properties of two cysteine proteinases (gingipains R), the products of two related but individual genes of Porphyromonas gingivalis. J. Biol. Chem. 1998, 273, 21648-21657.
14. Nakayama, K.; Ratnayake, D. B.; Tsukuba, T.; Kadowaki, T.; Yamamoto, K.; et al. Haemoglobin receptor protein is intragenically encoded by the cysteine proteinase-encoding genes and the haemagglutinin-encoding gene of Porphyromonas gingivalis. Mol. Microbiol. 1998, 27, 51-61.
15. Okamoto, K.; Nakayama, K.; Kadowaki, T.; Abe, N.; Ratnayake, D. B.; et al. Involvement of a lysine-specific cysteine proteinase in hemoglobin adsorption and heme accumulation by Porphyromonas gingivalis. J. Biol. Chem. 1998, 273, 21225-21231.
16. Genco, C. A.; Potempa, J.; Mikolajczyk-Pawlinska, J.; Travis, J. Role of gingipains R in the pathogenesis of Porphyromonas gingiualis-mediated periodontal disease. Clin, infect. Dis. 1999, 28, 456-465.
17. Graves, D. T.; Jiang, Y.; Genco, C. Periodontal disease: Bacterial virulence factors, host response and impact on systemic health. Curr. Opin. Infect. Dis. 2000, 13, 227-232.
18. Imamura, T. The role of gingipains in the pathogenesis of periodontal disease. J. Periodontol. 2003, 74, 111-118.
19. Abe, N.; Kadowaki, T.; Okamoto, K.; Nakayama, K.; Ohishi, M.; et al. Biochemical and functional properties of lysine-specific cysteine proteinase (Lys-gingipain) as a virulence factor of Porphyromonas gingivalis in periodontal disease. J. Biochem. (Tokyo) 1998, 123, 305-312.
20. Travis, J.; Potempa, J. Bacterial proteinases as targets for the development of second-generation antibiotics. Biochim. Biophys. Acta 2000, 1477, 35-50.
21. Kadowaki, T.; Yamamoto, K. Suppression of virulence of Porphyromonas gingivalis by potent inhibitors specific for gingipains. Curr. Protein Pept. Sci. 2003, 4, 451-458.
22. Curtis, M. A.; Kuramitsu, H. K.; Lantz, M.; Macrina, F. L.; Nakayama, K.; et al. Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis. J. Periodontal. Res. 1999, 34, 464-472.
23. ( 22) Pavloff, N.; Potempa, J.; Pike, R. N.; Prochazka, V.; Kiefer, M. C.; et al. Molecular cloning and structural characterization of the Arggingipain proteinase of Porphyromonas gingivalis. Biosynthesis as a proteinase-adhesin polyprotein. J. Biol. Chem. 1995. 270, 1007-1010.
24. Rangarajan, M.; Aduse-Opoku, J.; Slaney, J. M.; Young, K. A.; Curtis, M. A. The prpR1 and prR2 arginine-specific protease genes of Porphyromonas gingivalis W50 produce five biochemically distinct enzymes. Mol. Microbiol. 1997, 23, 955-965.
25. Gusman, H.; Travis, J.; Heimerhorst, E. J.; Potempa, J.; Troxler, R. F.; et al. Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease. Infect. Immun. 2001, 69, 1402-1408.
26. Snipas, S. J.; Stennicke, H. R.; Riedl, S.; Potempa, J.; Travis, J.; et al. Inhibition of distant caspase homologues by natural caspase inhibitors. Biochem. J. 2001, 357, 575-580.
27. Kadowaki, T.; Kitano, S.; Baba, A.; Takii, R.; Hashimoto, M.; et al. Isolation and characterization of a novel and potent inhibitor of Arggingipain from Streptomyces sp. strain FA-70. Biol. Chem. 2003, 384, 911-920.
28. Imamura, T.; Matsushita, K.; Travis, J.; Potempa, J. Inhibition of trypsin-like cysteine proteinases (gingipains) from Porphyromonas gingivalis by tetracycline and its analogues. Antimicrob. Agents Chemother. 2001, 45, 2871-2876.
29. ( 28) Potempa, J.; Pike, R.; Travis, J. Titration and mapping of the active site of cysteine proteinases from Porphyromonas gingivalis (gingi-pains) using peptidyl chloromethanes. Biol. Chem. 1997, 378, 223-230.
30. Curtis, M. A.; Aduse Opoku, J.; Rangarajan, M.; Gallagher, A.; Sterne, J. A.; et al. Attenuation of the virulence of Porphyromonas gingivalis by using a specific synthetic Kgp protease inhibitor. Infect. Immun. 2002, 70, 6968-6975.
31. J ournal of Medicinal Chemistry, 2006, Vol. 49, No. 5 1753
32. ( 30) Ekici, O. D.; Gotz, M. G.; James, K. E.; Li, Z. Z.; Rukamp, B. J.; et al. Aza-peptide Michael acceptors: A new class of inhibitors specific for caspases and other clan CD cysteine proteases. J. Med. Chem. 2004, 47, 1889-1892.
33. Krauser, J. A.; Potempa, J.; Travis, J.; Powers, J. C. Inhibition of arginine gingipains (RgpB and HRgpA) with benzamidine inhibitors: Zinc increases inhibitory potency. Biol. Chem. 2002, 383, 1193-1198.
34. Krauser, J. A.; Potempa, J.; Travis, J.; Powers, J. C. Inhibition of arginine gingipains (RgpB and HRgpA) with benzamidine inhibitors: Zinc increases inhibitory potency. Biol. Chem. 2002, 383, 1193-1198.
35. Otto, H. H.; Schirmeister, T. Cysteine proteases and their inhibitors. Chem. Reu. 1997, 97, 133-172.
36. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: Current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
37. Bohm, H. J. LUDI: Rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput. Aided Mol Des. 1992, 6, 593-606.
38. ( 35) Bohm, H. J. A novel computational tool for automated structure-based drug design. J. Mol. Recognit. 1993, 6, 131-137.
39. Berger, A.; Schechter, I. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos. Trans. R. Soc. London B Biol. Sci. 1970, 257, 249-264.
40. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234.
41. Eichinger, A.; Beisel, H. G.; Jacob, U.; Huber, R.; Medrano, F. J.; et al. Crystal structure of gingipain R: An Arg-specific bacterial cysteine proteinase with a caspase-like fold. EMBO J. 1999, 18, 5453-5462.
42. Bohm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des. 1994, 8, 243-256.
43. Ligand_Design 97 Molecular Modelling Program Package; 97.0 ed.; Molecular Simulations Inc.: San Diego, CA.
44. Steinmetzer, T.; Konishi, Y. Tripeptydyl pyridinium methyl ketones as potent active site inhibitors of thrombin. Bioorg. Med. Chem. Lett. 1996, 6, 1677-1682.
45. Grembecka, J.; Mucha, A.; Cierpicki, T.; Kafarski, P. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. J. Med. Chem. 2003, 46, 2641-2655.
46. Dyguda, E.; Grembecka, J.; Sokalski, W. A.; Leszczynski, J. Origins of the activity of PAL and LAP enzyme inhibitors: Toward ab initio binding affinity prediction. J. Am. Chem. Soc. 2005, 127, 1658-1659.
47. Insight 97 Molecular Modelling Program Package; 97.0 ed.; Molecular Simulations Inc.: San Diego, CA.
48. Discover, Molecular Modelling Program Package; 97.0 ed.; Molecular Simulation: San Diego, CA.
49. Steinmetzer, T.; Zhu, B. Y.; Konishi, Y. Potent bivalent thrombin inhibitors: Replacement of the scissile peptide bond at P(I)-P(I)′ with arginyl ketomethylene isosteres. J. Med. Chem. 1999, 42, 3109-3115.